Development of multipurpose technologies products for pregnancy and STI prevention: update on polyphenylene carboxymethylene MPT gel development†.
| Autor: | Weitzel M; Yaso Therapeutics Inc, Scottsdale, AZ, USA., North BB; Yaso Therapeutics Inc, Scottsdale, AZ, USA., Waller D; Yaso Therapeutics Inc, Scottsdale, AZ, USA.; College of Pharmacy, University of Illinois, Chicago, IL, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Biology of reproduction [Biol Reprod] 2020 Aug 04; Vol. 103 (2), pp. 299-309. |
| DOI: | 10.1093/biolre/ioaa087 |
| Abstrakt: | Current modern contraceptives rely heavily on the use of hormones. These birth control drug products, including pills, patches, injections, and IUDS, have been extremely beneficial to millions of women and their families over the past 50 years. But a surprisingly high number of women abandon such modern methods, many because they cannot tolerate the side effects and others because they have medical issues for which hormonal methods are contraindicated. In addition, modern hormonal methods are simply not available to many women. The extent of this problem is steadily becoming more apparent. We present the case for developing simple nonhormonal vaginal products that women can use when needed, ideal products that are multipurpose and offer both contraception and sexually transmitted disease protection. Gel-based vaginal products are particularly well suited for this purpose. Gels are easy to use, highly acceptable to many women, and can be safely formulated to enhance natural vaginal defenses against infection. However, the development of a new chemical entity for this application faces significant technical and regulatory hurdles. These challenges and our solutions are described for polyphenylene carboxymethylene (PPCM), a novel topical drug in a vaginal gel nearing human clinical trials. We have advanced PPCM from benchtop to IND-enabling studies and provide a brief description of the complex development process. We also describe a simple lab assay which can be used as a biomarker for contraceptive activity to enable pharmacodynamic studies in vaginal contraceptive development, both preclinically and in early human clinical trials. (© The Author(s) 2020. Published by Oxford University Press on behalf of Society for the Study of Reproduction.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|